Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer.
about
Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell linesSurvival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature.Successful in vivo hyperthermal therapy toward breast cancer by Chinese medicine shikonin-loaded thermosensitive micelle.Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000.The prediction models for postoperative overall survival and disease-free survival in patients with breast cancerLong-term survival analysis of korean breast cancer patients at a single center: improving outcome over time.Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer.Survival differences among women with de novo stage IV and relapsed breast cancer.Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage.Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).Retrospective analysis of metastatic behaviour of breast cancer subtypesDefining the survival benchmark for breast cancer patients with systemic relapseNanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical PracticeEthnic differences in breast cancer survival: status and determinants.Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase.Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCHas racial difference in cause-specific death improved in older patients with late-stage breast cancer?Human epidermal growth factor receptor 2 protein expression between primary breast cancer and paired asynchronous local-regional recurrences.Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status.Trends in presentation, management and survival of patients with de novo metastatic breast cancer in a Southeast Asian setting.Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview.Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years.Invasive procedures in the elderly after stage IV cancer diagnosis.High-cost imaging in elderly patients with stage IV cancer.Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy.Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.The influence of race and ethnicity on the biology of cancerValue of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer.Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.Pituitary metastasis from breast cancer presenting as diabetes insipidus.A review of body size and breast cancer risk in Hispanic and African American women.Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer.Identifying the potential long-term survivors among breast cancer patients with distant metastasis.Therapies for triple negative breast cancer.Eribulin long-term response and rechallenge: report of two clinical cases.
P2860
Q26745420-46738AC7-7077-4159-9208-19F3BF26F468Q28483816-5051895E-1350-4596-9319-7667667202DFQ30992939-637A702F-CCC0-47AA-9A61-C962F47D1541Q33758385-88D2FAB6-7B4A-4472-B003-7768AB7476CDQ33858930-A6C1288A-CCD1-46EB-922E-850C79FBDFBDQ33891155-37835549-0E31-4DB3-A8DF-33C1BF81072BQ33941558-22CB61D5-79EB-4BFE-936B-22D291EA886BQ34033757-11257FA9-F210-4988-A861-512AF7995C58Q34231099-D478765A-2610-4211-B8DF-DBA414202219Q34243127-07457E1B-6B8F-4EC3-81A7-94F821940819Q34613506-35AE8F1B-3A52-44CD-AF76-E391541FEF7FQ35252752-86E2F08D-0F8E-42EC-B7CC-0B20F8562C47Q35459288-1F36D391-4122-4147-A291-48CAD205B9B9Q35507680-7FA016D2-86CB-4BD8-819C-59E75C3896BCQ35667196-25808040-FD03-411A-AF86-A5672780842CQ35668954-EBE84F38-2BC4-46C7-9EFF-40EC383C411AQ35678734-D9686B55-79F0-4BEE-B77F-3C4E231AD7FBQ35845089-69E5BBD8-F3D0-4964-BC79-C13707C3F0E5Q35847455-C4CBF0AE-9569-48E1-B250-10ABCEDE1867Q36078361-12F25FE7-93E5-4B59-B3B0-115A538B2E84Q36230879-E3D471E9-BC7A-497D-9427-D37E5078CA77Q36249087-2D7BDB00-2DFC-46BE-9587-0B805C04F4EAQ36249905-E224055E-77D6-4DC0-8178-7ADE5EBFDFF8Q36630732-77BD4AF5-8B08-4887-A180-8E2C364C6DCDQ36672852-E7C2B3B0-7DB0-4111-9A0C-829E35C1ED10Q36685202-83D74F29-6562-4E6D-98E3-46728EACE405Q36727374-2FB8769F-DDCA-47C9-AE3A-CFAE04C7243FQ36779798-B2DA58C6-39EB-4084-9FCD-77ADE015738FQ36788277-9DBB2354-D6FB-432E-8AA5-4BDD7234845EQ36916990-CD46196F-0971-4B64-9284-E60265216300Q36981612-FCC7C972-4453-427D-8FDB-FF239BA7C26FQ37129663-C0463CD7-119A-4691-9A50-FAF9121E8616Q37236305-7F2A7338-A670-436E-BF7A-D7C6F02C4FA1Q37695495-AF0FA8A9-D456-4569-9077-273E5A4D6658Q37704324-447AECB3-6317-456E-B4F3-3B11EA7DC2C7Q37877651-21F31ADA-A8DD-43FC-A5AD-05A94D1838F2Q37950522-533552F5-2245-4B83-8555-65A34A30E407Q38417762-064C678D-BBE2-4CDA-B89C-40BECBE8333BQ38424397-6C272012-7880-42CF-947F-B1BC217B032DQ38686613-C921A522-7814-4439-B7B5-4FB76C733414
P2860
Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Trends in survival over the pa ...... gnosed stage IV breast cancer.
@en
Trends in survival over the pa ...... gnosed stage IV breast cancer.
@nl
type
label
Trends in survival over the pa ...... gnosed stage IV breast cancer.
@en
Trends in survival over the pa ...... gnosed stage IV breast cancer.
@nl
prefLabel
Trends in survival over the pa ...... gnosed stage IV breast cancer.
@en
Trends in survival over the pa ...... gnosed stage IV breast cancer.
@nl
P2093
P2860
P356
P1476
Trends in survival over the pa ...... gnosed stage IV breast cancer.
@en
P2093
Aman U Buzdar
Ana M Gonzalez-Angulo
Gabriel N Hortobagyi
Kristine Broglio
Shaheenah Dawood
P2860
P304
P356
10.1200/JCO.2007.14.1168
P407
P577
2008-08-25T00:00:00Z